Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies Academic Article uri icon

Overview

MeSH Major

  • Heart
  • Hematologic Neoplasms
  • Imidazoles
  • Long QT Syndrome
  • Protein Kinase Inhibitors
  • Pyridazines

abstract

  • Ponatinib is associated with a low risk of QTc prolongation in patients with refractory hematological malignancies.

publication date

  • June 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3668123

Digital Object Identifier (DOI)

  • 10.1007/s00280-013-2160-7

PubMed ID

  • 23609479

Additional Document Info

start page

  • 1599

end page

  • 607

volume

  • 71

number

  • 6